Allele-specific silencing as treatment for gene duplication disorders: proof-of-principle in autosomal dominant leukodystrophy.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
01 07 2019
Historique:
received: 30 03 2018
revised: 16 01 2019
accepted: 31 03 2019
pubmed: 31 5 2019
medline: 19 5 2020
entrez: 31 5 2019
Statut: ppublish

Résumé

Allele-specific silencing by RNA interference (ASP-siRNA) holds promise as a therapeutic strategy for downregulating a single mutant allele with minimal suppression of the corresponding wild-type allele. This approach has been effectively used to target autosomal dominant mutations and single nucleotide polymorphisms linked with aberrantly expanded trinucleotide repeats. Here, we propose ASP-siRNA as a preferable choice to target duplicated disease genes, avoiding potentially harmful excessive downregulation. As a proof-of-concept, we studied autosomal dominant adult-onset demyelinating leukodystrophy (ADLD) due to lamin B1 (LMNB1) duplication, a hereditary, progressive and fatal disorder affecting myelin in the CNS. Using a reporter system, we screened the most efficient ASP-siRNAs preferentially targeting one of the alleles at rs1051644 (average minor allele frequency: 0.45) located in the 3' untranslated region of the gene. We identified four siRNAs with a high efficacy and allele-specificity, which were tested in ADLD patient-derived fibroblasts. Three of the small interfering RNAs were highly selective for the target allele and restored both LMNB1 mRNA and protein levels close to control levels. Furthermore, small interfering RNA treatment abrogates the ADLD-specific phenotypes in fibroblasts and in two disease-relevant cellular models: murine oligodendrocytes overexpressing human LMNB1, and neurons directly reprogrammed from patients' fibroblasts. In conclusion, we demonstrated that ASP-silencing by RNA interference is a suitable and promising therapeutic option for ADLD. Moreover, our results have a broad translational value extending to several pathological conditions linked to gene-gain in copy number variations.

Identifiants

pubmed: 31143934
pii: 5506062
doi: 10.1093/brain/awz139
doi:

Substances chimiques

Lamin Type B 0
RNA, Small Interfering 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1905-1920

Informations de copyright

© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Auteurs

Elisa Giorgio (E)

University of Torino, Department of Medical Sciences, Torino, Italy.

Martina Lorenzati (M)

University of Torino, Department of Neuroscience Rita Levi Montalcini and Neuroscience Institute Cavalieri Ottolenghi (NICO), Orbassano, Torino, Italy.

Pia Rivetti di Val Cervo (P)

University of Milan, Department of Biosciences, Laboratory of Stem Cell Biology and Pharmacology of Neurodegenerative Diseases, Milan, Italy.

Alessandro Brussino (A)

University of Torino, Department of Medical Sciences, Torino, Italy.

Manuel Cernigoj (M)

University of Milan, Department of Biosciences, Laboratory of Stem Cell Biology and Pharmacology of Neurodegenerative Diseases, Milan, Italy.

Edoardo Della Sala (E)

University of Torino, Department of Medical Sciences, Torino, Italy.

Anna Bartoletti Stella (A)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Bologna, Italy.

Marta Ferrero (M)

University of Torino, Department of Medical Sciences, Torino, Italy.

Massimiliano Caiazzo (M)

Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Universiteitsweg 99, CG, Utrecht, The Netherlands.
Department of Molecular Medicine and Medical Biotechnology, University of Naples 'Federico II', Naples, Italy.

Sabina Capellari (S)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Bologna, Italy.
University of Bologna, Department of Biomedical and Neuromotor Sciences, Bologna, Italy.

Pietro Cortelli (P)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Bologna, Italy.
University of Bologna, Department of Biomedical and Neuromotor Sciences, Bologna, Italy.

Luciano Conti (L)

University of Trento, Centre for Integrative Biology (CIBIO), Laboratory of Computational Oncology, Trento, Italy.

Elena Cattaneo (E)

University of Milan, Department of Biosciences, Laboratory of Stem Cell Biology and Pharmacology of Neurodegenerative Diseases, Milan, Italy.
National Institute of Molecular Genetics (INGM) Romeo and Enrica Invernizzi, Milano, Italy.

Annalisa Buffo (A)

University of Torino, Department of Neuroscience Rita Levi Montalcini and Neuroscience Institute Cavalieri Ottolenghi (NICO), Orbassano, Torino, Italy.

Alfredo Brusco (A)

University of Torino, Department of Medical Sciences, Torino, Italy.
Città della Salute e della Scienza University Hospital, Medical Genetics Unit, Torino, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH